[1] Argentiero A, Solimando AG, Brunetti O, et al.Skeletal metastases of unknown primary: biological landscape and clinical overview[J]. Cancers (Basel), 2019,11(9):1270-1287.DOI: 10.3390/cancers11091270. [2] Dwan K, Phillipi CA, Steiner RD, et al. Bisphosphonate therapy for osteogenesis imperfecta[J]. Cochrane Database Syst Rev, 2014,23(7):CD005088. DOI: 10.1002/14651858. CD005088.pub4. [3] Hernandez M, Phulpin B, Mansuy L, et al.Use of new targeted cancer therapies in children: effects on dental development and risk of jaw osteonecrosis: a review[J]. J Oral Pathol Med, 2017,46(5):321-326. DOI: 10.1111/jop.12516. [4] Oledzka E, Sobczak M, Kolmas J, et al.Selenium-substituted hydroxyapatite/biodegradable polymer/pamidronate combined scaffold for the therapy of bone tumour[J]. Int J Mol Sci, 2015,16(9):22205-22222. DOI: 10.3390/ijms160922205. [5] Şahin O, Odabaşı O, Aliyev T, et al.Risk factors of medication-related osteonecrosis of the jaw: a retrospective study in a Turkish subpopulation[J]. J Korean Assoc Oral Maxillofac Surg, 2019,45(2):108-115. DOI: 10.5125/jkaoms.2019.45.2.108. [6] Krstevska S, Stavric SG, Cevrevska L, et al.Osteonecrosis of the jaw after bisphosphonates treatment in patients with multiple myeloma[J]. Med Arch, 2015,69(6):367-370. DOI: 10.5455/medarh.2015.69.367-370. [7] Kim DS, Kim JH, Ohe JY, et al.Bisphosphonate-related osteonecrosis of the jaw in a patient with osteoporosis following treatment of testicular cancer: a case report[J]. J Korean Assoc Oral Maxillofac Surg, 2015,41(6):327-331. DOI: 10.5125/jkaoms.2015.41.6.327. [8] Kim HJ, Park TJ, Ahn KM.Bisphosphonate-related osteonecrosis of the jaw in metastatic breast cancer patients: a review of 25 cases[J]. Maxillofac Plast Reconstr Surg, 2016,38(1):6. DOI: 10.1186/s40902-016-0052-6. [9] Pittenger MF, Mackay AM, Beck SC, et al.Multilineage potential of adult human mesenchymal stem cells[J]. Science, 1999,284(5411):143-147. DOI: 10.1126/science.284. 5411.143. [10] Kawai M, Rosen CJ.PPARγ: a circadian transcription factor in adipogenesis and osteogenesis[J]. Nat Rev Endocrinol, 2010,6(11):629-636. DOI: 10.1038/nrendo.2010.155. [11] Kiper P, Saito H, Gori F, et al.Cortical-bone fragility--insights from sFRP4 deficiency in Pyle's disease[J]. N Engl J Med, 2016,374(26):2553-2562. DOI: 10.1056/NEJMoa1509342. [12] Zhang L, Liu W, Zhao J, et al.Mechanical stress regulates osteogenic differentiation and RANKL/OPG ratio in periodontal ligament stem cells by the Wnt/β-catenin pathway[J]. Biochim Biophys Acta, 2016,1860(10):2211-2219. DOI: 10.1016/j.bbagen.2016.05.003. [13] Haraguchi R, Kitazawa R, Mori K, et al.sFRP4-dependent Wnt signal modulation is critical for bone remodeling during postnatal development and age-related bone loss[J]. Sci Rep, 2016,6:25198. DOI: 10.1038/srep25198. [14] Marx RE.Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic[J]. J Oral Maxillofac Surg, 2003,61(9):1115-1117. DOI: 10.1016/s0278-2391(03)00720-1. [15] Saia G, Blandamura S, Bettini G, et al.Occurrence of bisphosphonate-related osteonecrosis of the jaw after surgical tooth extraction[J]. J Oral Maxillofac Surg, 2010,68(4):797-804. DOI: 10.1016/j.joms.2009.10.026. [16] Russell RG, Xia Z, Dunford JE, et al.Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy[J]. Ann N Y Acad Sci, 2007,1117:209-257. DOI: 10.1196/annals.1402.089. [17] Liu S, Liu D, Chen C, et al.MSC Transplantation improves osteopenia via epigenetic regulation of notch signaling in lupus[J]. Cell Metab, 2015,22(4):606-618. DOI: 10.1016/j.cmet.2015.08.018. [18] Saldanha S, Shenoy VK, Eachampati P, et al.Dental implications of bisphophonate-related osteonecrosis[J]. Gerodontology, 2012,29(3):177-187. DOI: 10.1111/j.1741-2358.2012.00622.x. [19] Gao SY, Zheng GS, Wang L, et al.Zoledronate suppressed angiogenesis and osteogenesis by inhibiting osteoclasts formation and secretion of PDGF-BB[J]. PLoS One, 2017,12(6):e0179248. DOI: 10.1371/journal.pone.0179248. [20] Gao SY, Lin RB, Huang SH, et al.PDGF-BB exhibited therapeutic effects on rat model of bisphosphonate-related osteonecrosis of the jaw by enhancing angiogenesis and osteogenesis[J]. Bone, 2021,144:115117. DOI: 10.1016/j.bone.2019.115117. [21] Wilches-Buitrago L, Viacava PR, Cunha FQ, et al.Fructose 1,6-bisphosphate inhibits osteoclastogenesis by attenuating RANKL-induced NF-κB/NFATc-1[J]. Inflamm Res, 2019,68(5):415-421. DOI: 10.1007/s00011-019-01228-w. [22] Gupta M, Gupta N.Bisphosphonate related jaw osteonecrosis[M]. Treasure Island (FL): StatPearls Publishing, 2021. |